Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05616013 |
Recruitment Status :
Active, not recruiting
First Posted : November 14, 2022
Last Update Posted : February 1, 2024
|
Sponsor:
Eli Lilly and Company
Collaborator:
Versanis Bio, Inc.
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | May 20, 2024 |
Estimated Study Completion Date : | June 17, 2025 |